LGALS9 and neoplasm: Similarly, galectin-9 also acts as a competitive inhibitor by blocking the VCAM1-α4β1 interactions, thereby reducing tumor cell adhesion to the vascular endothelium and consequent tumor cell extravasation and metastasis (145).